#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Rhabdomyosarcoma recurrent Familial amyotrophic lateral sclerosis Osteogenesis imperfecta Mucopolysaccharidosis II Hereditary motor and sensory neuropathy Squamous cell carcinoma of head and neck Lip and/or oral cavity cancer Endometrial cancer recurrent Chronic myelomonocytic leukaemia Dermatomyositis Leukodystrophy Adenocarcinoma pancreas Mucopolysaccharidosis I Glioblastoma multiforme Extra-osseous Ewing's sarcoma recurrent More trials…

    Learn about Rare Diseases

    Prader-Willi syndrome Atypical haemolytic uraemic syndrome – Life with Disease Vascular malformation Cerebral arteriovenous malformation haemorrhagic Piriformis syndrome – Life with Disease Choroid melanoma – Treatment Cytokine release syndrome Pulmonary fibrosis – Life with Disease Mucopolysaccharidosis III – Diagnostics Nodal marginal zone B-cell lymphoma – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    F1245/05 TRV045 Spironolactone Mva-Hbvac CARBOMER 980 Ivabradine Hydrochloride Mifamurtide Chlorambucil Zanidatamab A52 Adrenaline Acid Tartrate Bp Fenoterol Hydrobromide Ravulizumab Cisatracurium Besilate BGB-16673 Gad20-209-Fsp-A3 Avalotcagene Ontaparvovec Octreotide Infigratinib Botensilimab More therapies…

    Learn about Your Condition

    Acute coronary syndrome Pathogen resistance Inclusion body myositis Anxiety Psychogenic seizure Myocarditis Asymptomatic HIV infection Glomerulonephritis chronic Dysmenorrhoea Coagulopathy Glaucoma Endolymphatic hydrops Dry mouth Generalised anxiety disorder Uterine leiomyoma More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Nutritional and Metabolic Diseases

  • Study comparing semaglutide with insulin glargine in overweight adults with type 2 diabetes: effectiveness of combined treatment versus insulin alone

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Type 2 diabetes mellitus
    • Overweight
    Investigated Drugs:
    • Insulin Glargine
    • Semaglutide
    Czechia Greece Italy Portugal Romania Slovakia +1

  • Study of Metformin Treatment to Maintain Type 2 Diabetes Remission in Patients After Bariatric Surgery

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Diabetes mellitus
    Investigated Drugs:
    • Metformin Embonate
    France

  • Study on the Safety and Effectiveness of Crofelemer for Children with Microvillus Inclusion Disease (MVID)

    Not recruiting

    4 1
    Investigated Diseases:
    • Microvillous inclusion disease
    Investigated Drugs:
    • Crofelemer
    Italy

  • Study on the Effectiveness and Safety of Lanifibranor for Adults with Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH) and Liver Fibrosis Stages F2/F3

    Not recruiting

    3 1
    Investigated Drugs:
    • Lanifibranor
    Belgium Bulgaria Czechia France Germany Hungary +5

  • Study of Tirzepatide for Reducing Obesity and Related Health Issues in Adolescents

    Not recruiting

    3 1
    Investigated Drugs:
    • Tirzepatide
    France Germany Spain

  • Study on the Effects and Safety of Ladarixin for Adults and Adolescents with Recent Onset Type 1 Diabetes

    Not recruiting

    2 1
    Investigated Diseases:
    • Type 1 diabetes mellitus
    Investigated Drugs:
    • Ladarixin
    Belgium Germany Italy
Previous Page
1 … 41 42 43 44 45 … 61
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!